"Methadone" from_date:2012

Methadone: an analysis of adverse effects reported in France Prescrire IN ENGLISH - Spotlight ''Methadone: an analysis of adverse effects reported in France'', 1 July 2024 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Awards * Advancing * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Methadone: an analysis of adverse effects reported in France SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90 Spotlight * 100 most recent * Archives Methadone: an analysis

Methadone for Surgical Patients View of Methadone for Surgical Patients | Canadian Journal of Health Technologies Return to Article DetailsMethadone for Surgical Patients

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 0 NUMBER 0 | Month 20241Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone TherapyKatherine M. Robinson1, Seenae Eum2, Zeruesenay Desta3, Rachel F. Tyndale4, Andrea Gaedigk5,6, Richard C. Crist7, Cyrine E. Haidar8, Alan L. Myers9, Caroline F. Samer10, Andrew A. Somogyi11, Pablo Zubiaur12, Otito F. Iwuchukwu13, Michelle Whirl- Carrillo14, Teri E. Klein14, Kelly E. Caudle8, Roseann S. Donnelly8,15 and Evan D. Kharasch16,*Methadone is a mu (μ) opioid receptor agonist used clinically in adults and children to manage opioid use disorder, neonatal abstinence syndrome, and acute and chronic pain

Laxatives and Erectile Dysfunction Medications to Treat Side Effects of Opioid Agonist and Methadone Maintenance Therapy Laxatives and Erectile Dysfunction Medications to Treat Side Effects of Opioid Agonist and Methadone Maintenance Therapy | CADTH Skip to main content * About * Collaboration/Outreach * Patient/Community * Careers * Contact * My CADTH * FR * Reports * Reports . Laxatives and Erectile Dysfunction Medications to Treat Side Effects of Opioid Agonist and Methadone Maintenance Therapy Copied to clipboard Laxatives and Erectile Dysfunction Medications to Treat Side Effects of Opioid Agonist and Methadone Maintenance Therapy ( Last Updated : June 22, 2021) Project Line: Health Technology Review Project Sub Line: Rapid Review Project Number: RC1364-000 DetailsQuestion1

Efficacy and safety of buprenorphine and methadone for the treatment of opioid use disorder MAY 2021OPIOID USE DISORDEROPIOID USE DISORDER (OUD) „The illicit use and misuse of opioids increase the risk of developing opioid use disorder (OUD), impair one’s well-being and increase the risk of fatal overdose. „Providing treatment using a harm reduction approach means mitigating the negative consequences of opioid use rather than eliminating the behaviour at all costs, in order to maximize treatment retention. „Any qualified professional can prescribe opioid agonist therapy (OAT), including specialized nurse practitioners, according to their class of specialization. •/The requirement to obtain an exemption from the federal government to prescribe methadone

Potential improvement in spatial accessibility of methadone treatment with integration into other outpatient substance use disorder treatment programs, New York City, 2024. Methadone is an effective treatment for opioid use disorder; however, its provision in the US is limited to federally-regulated opioid treatment programs (OTP). Expansion of methadone treatment into non-OTP substance use disorder (SUD) treatment programs ('expanded methadone treatment access') is a promising intervention to increase access. We performed a cross-sectional geospatial analysis of public transit times to OTPs, expanded methadone treatment access, and other healthcare facilities as of March, 2024 in New York City (NYC). We estimated one-way public transit travel time and compared travel times using population

Guideline recommends buprenorphine or methadone as first-line treatment for opioid use disorder (high certainty). GIM/FP/GP: [Formula: see text] Public Health: [Formula: see text].

Barriers to implementing contingency management at a methadone treatment clinic: A qualitative study at a tertiary hospital in Tanzania. Contingency management in addiction behaviors has been widely applied in high income settings. Contingency management entails modification of behavior via the control or manipulation of consequences (contingencies) to the behavior. While a need exists for contingency management in low- and middle- income settings, specifically those of the sub-Saharan Africa region, uptake is low relative to high income settings. This study assessed barriers to implementation of contingency management for methadone treatment clients at the outpatient clinic of a tertiary hospital in Tanzania. This study employed a qualitative design and was conducted at Mbeya Zonal Referral

First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations Use of buprenorphine or methadone to treat opioid use disorder is recommended in pregnancy; however, their teratogenic potential is largely unknown. To compare the risk of congenital malformations following in utero exposure to buprenorphine vs methadone. This population-based cohort study used health care utilization data from publicly insured Medicaid beneficiaries in the US from 2000 to 2018. A total of 13 360 pregnancies with enrollment from 90 days prior to pregnancy start through 1 month after delivery and first trimester use of buprenorphine or methadone were included and linked to infants. Data were analyzed from July to December 2022. A pharmacy dispensing of buprenorphine or a code

Effect of Acupuncture for Methadone Reduction : A Randomized Clinical Trial. Methadone maintenance treatment (MMT) is effective for managing opioid use disorder, but adverse effects mean that optimal therapy occurs with the lowest dose that controls opioid craving. To assess the efficacy of acupuncture versus sham acupuncture on methadone dose reduction. Multicenter, 2-group, randomized, sham -controlled trial. (Chinese Clinical Trial Registry: ChiCTR2200058123). 6 MMT clinics in China. Adults aged 65 years or younger with opioid use disorder who attended clinic daily and had been using MMT for at least 6 weeks. Acupuncture or sham acupuncture 3 times a week for 8 weeks. The 2 primary outcomes were the proportion of participants who achieved a reduction in methadone dose of 20% or more compared

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. Previous studies on the comparative effectiveness between buprenorphine and methadone provided limited evidence on differences in treatment effects across key subgroups and were drawn from populations who use primarily heroin or prescription opioids, although fentanyl use is increasing across North America. To assess the risk of treatment discontinuation and mortality among individuals receiving buprenorphine/naloxone vs methadone for the treatment of opioid use disorder. Population-based retrospective cohort study using linked health administrative databases in British Columbia, Canada. The study included treatment recipients between January 1, 2010, and March 17, 2020, who were 18 years or older

Methadone's Moment. This work discusses unfettering methadone from outdated regulations to empower patients to access treatment and advocate for methadone's expansion in their local communities by working with pharmacies and local health systems.

METHA-NeP: effectiveness and safety of methadone for neuropathic pain: a controlled randomized trial In this randomized, double-blind, parallel placebo-controlled clinical trial, we evaluated the efficacy of methadone as an add-on therapy for people with chronic neuropathic pain (NP). Eighty-six patients were randomly assigned to receive methadone or placebo for 8 weeks. The primary outcome was the proportion of participants achieving at least 30% pain relief from baseline using a 100-mm pain Visual Analogue Scale. Secondary outcomes included global impression of change, NP symptoms, sleep quality, quality of life, pain interference in daily activities, and mood. A larger number of responders were found in the methadone (68%), compared to the placebo (33%) arm; risk difference 33.6%; 95% confidence

Effect of intraoperative methadone in robot-assisted cystectomy on postoperative opioid requirements: A randomized clinical trial. Postoperative pain management is a challenge after robot-assisted cystectomy (RAC). Methadone has a long duration of action, and we therefore hypothesized that a single dose of intraoperative methadone would reduce postoperative opioid requirements and pain intensity in bladder cancer patients undergoing RAC. We conducted a blinded randomized controlled clinical trial from July 2020 to August 2023. Patients scheduled to undergo RAC because of bladder cancer were randomized to receive intraoperative methadone (0.15 mg/kg) or morphine (0.15 mg kg) 1 h before endotracheal extubation. The primary outcome was opioid requirements after 24 h. Secondary outcomes were opioid

Early Results of Implementing Rapid Methadone Titration for Hospitalized Patients: A Case Series. With the increase in illicit fentanyl use in the USA, hospitals face challenges managing opioid withdrawal and opioid use disorder (OUD). To improve opioid withdrawal and OUD treatment among hospitalized patients with daily fentanyl use, we developed a rapid methadone titration (RMT) protocol. We describe development, implementation, and outcomes during the first 12 weeks. We analyzed electronic health record data of hospitalizations seen by the Addiction Consult Team (ACT) for methadone initiation between 9/11/23 and 12/3/23. Adults aged 18-64 reporting daily fentanyl use, desiring methadone, and without end-stage organ damage or critical illness were RMT eligible. We characterized patients who

Cognitive control in individuals with heroin use disorder after prolonged methadone maintenance treatment. Although impaired cognitive control is common during the acute detoxification phase of substance use disorders (SUD) and is considered a major cause of relapse, it remains unclear after prolonged methadone maintenance treatment (MMT). The aim of the present study was to elucidate cognitive

Validation of the alcohol, smoking and substance involvement screening test (ASSIST) for identifying methamphetamine use among people on methadone maintenance treatment in Vietnam. Identifying those who use methamphetamine or are at high risk of using methamphetamine is essential so that early, appropriate intervention can be made. This study evaluated the use of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for identifying methamphetamine use among people on methadone maintenance treatment (MMT) in Vietnam. From June 2021 to May 2023, all people on MMT at 15 methadone clinics in Hanoi and Ho Chi Minh City, Vietnam, were invited to participate in this study. Participants underwent a face-to-face interview to complete the 8-item ASSIST. Participants also had

High BMI is a specific risk factor for drug-related mortality in patients receiving methadone: A case control study. Long-term treatment of opioid dependence with the opioid agonist therapy (OAT) methadone can lead to significant weight gain. This study investigated whether OAT patients with a body mass index (BMI) deemed overweight (≥25) are at increased risk of mortality. A retrospective case prescribed methadone (vs buprenorphine) (mean aOR = 1.916; 95% CI = 1.138-3.227). There was no significant effect of gender (mean aOR = 0.844; 95% CI = 0.612-1.162) or methadone dose (aOR = 0.995; 95% CI = 0.988-1.001) on incidence of death. Acute drug toxicity was the predominant underlying cause of death for healthy and overweight people (46% of cases in both groups), with cancer (21% of cases

State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset. US regulatory changes allowed for additional methadone take-home doses following COVID-19 onset. How dispensing practices changed and which factors drove variation remains unexplored. We determined daily methadone dispensing trajectories over six months before and after regulatory changes due to COVID-19 using state sequence analysis and explored correlates. Retrospective chart review of electronic health records. Nine opioid treatment programs (OTPs) across nine US states. Adults initiating treatment in 2019 (n = 328) vs. initiating 1 month after the COVID-19 regulatory changes of March 2020 (n = 376). Type of daily methadone

The effectiveness of a transtheoretical model based on health education intervention on adherence to methadone maintenance treatment: a quasi-experimental study. Treatment adherence is one of the major challenges in methadone maintenance treatment (MMT). This study aimed to investigate the effect of educational intervention using a transtheoretical model (TTM) on adherence to MMT. This quasi